Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors
Evaluate the Efficacy and Safety of HLX10, PD-1 mAb, in Combination With HLX07, EGFR mAb, in Patients With Advanced Head And Neck Tumors
Sponsor: Shanghai Henlius Biotech
This PHASE2 trial investigates Head and Neck Squamous Cell Carcinoma and is currently ongoing. Shanghai Henlius Biotech leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Aug 2025 — Present [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
Jun 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE2
-
Oct 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
Status: Not Yet Recruiting → Active Not Recruiting
-
Jan 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Henlius Biotech
For direct contact, visit the study record on ClinicalTrials.gov .